CNTA - CIK 0001847903
The table below shows Centessa Pharmaceuticals plc's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$193.82M | -$142.06M | -$160.34M | -$200.55M | -$135.11M | -$10.63M |
| Capital expenditure | $371.00K | $34.00K | $169.00K | $1.14M | $186.00K | $0.00 |
| Investing cash flow | -$418.53M | $31.27M | -$127.00M | -$931.00K | $63.26M | $0.00 |
| Dividends paid | - | - | - | - | - |
Centessa Pharmaceuticals plc reported operating cash flow of -$193.82M for fiscal year 2025. That is down 36.4% from -$142.06M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$5.83M (FY 2019) to -$193.82M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | $12.00K | $0.00 |
| Financing cash flow | $291.53M | $364.75M | $21.12M | $457.00K | $660.15M | $1.36M |